Table 2.
Univariate analysis of demographics, clinical findings and treatment factors associated with mortality of drug-resistant A. baumannii VAP patients.
| Variable | Survivors (n = 22) | Non-Survivors (n = 38) | p Value |
|---|---|---|---|
| Gender, n (%) | |||
| Female | 6 (20.7) | 23 (79.3) | 0.017 |
| Male | 16 (51.6) | 15 (48.4) | |
| Age (years), mean (SD) | 60.77 (16) | 65.79 (14.3) | 0.214 |
| Severity score on ICU admission, mean (SD) | |||
| APACHE II | 17.64 (7.1) | 21.63 (9.1) | 0.082 |
| SOFA | 9.41 (4.3) | 12.71 (3.8) | 0.003 |
| SAPS II | 41.73 (15.2) | 51.55 (10.1) | 0.011 |
| Sepsis status on ICU admission, n (%) | |||
| Sepsis | 19 (35.2) | 35 (64.8) | 0.659 |
| Shock | 9 (45) | 11 (55) | 0.401 |
| Chronic diseases, n (%) | 12 (27.9) | 31 (72.1) | 0.038 |
| Coma GCS <9, n (%) | 4 (50) | 4 (50) | 0.449 |
| Admission type, n (%) | |||
| Surgery | 6 (35.3) | 11 (64.7) | 0.981 |
| Internal disease | 11 (37.9) | 18 (62.1) | |
| Trauma | 5 (35.7) | 9 (64.3) | |
| Reintubation, n (%) | 8 (42.1) | 11 (57.9) | 0.577 |
| Surgical intervention, n (%) | 6 (26.1) | 17 (73.9) | 0.271 |
| Tracheostomy prior to VAP, n (%) | 1 (12.5) | 7 (87.5) | 0.238 |
| RBC transfusion prior to VAP, n (%) | 9 (25) | 27 (75) | 0.03 |
| RBC (units), median (IQR) | 0 (0–2.3) | 2 (0–5) | 0.044 |
| LOS (days), median (IQR) | |||
| Hospital prior to ICU | 0.5 (0–3.5) | 1 (0–4) | 0.568 |
| ICU prior to MV | 0 (0–0.3) | 0 (0–0.25) | 0.876 |
| ICU prior to VAP | 8 (5.8–11) | 9.5 (5.8–15) | 0.442 |
| Hospital prior to MV | 0 (0–1.3) | 0.5 (0–4) | 0.341 |
| Hospital prior to VAP | 9.5 (6–14) | 13 (7.5–20) | 0.126 |
| MV prior to VAP (days), median (IQR) | 9 (5–11.5) | 8 (5–15.3) | 0.729 |
| Antibiotic treatment prior to VAP (days), median (IQR) | 10 (6–14.8) | 14 (7.8–20) | 0.164 |
SD—standard deviation, IQR—interquartile range, ICU—intensive care unit, APACHE II—Acute Physiology and Chronic Health Evaluation score II, SAPS II—Simplified Acute Physiology Score II, SOFA—Sequential Organ Failure Assessment score, GCS—Glasgow coma scale, RBC—red blood cells, BLI—β-lactamase inhibitors, LOS—length of stay, MV—mechanical ventilation, and VAP—ventilator associated pneumonia.